JPMorgan Chase & Co. Raises Holdings in Sana Biotechnology, Inc. $SANA

Key Points

• JPMorgan Chase boosted its stake in Sana by 180.8% in Q3, adding 1,375,029 shares to hold 2,135,444 shares (about 0.80% of the company) valued at $7.58 million.
• Multiple large institutions — including Vanguard, Baillie Gifford, Millennium, Marex and Corient — also increased positions, leaving institutional investors with a combined 88.23% ownership of the stock.
• Sana shares trade around $2.68, below the 50- and 200-day moving averages, the company reported a Q (Mar 3) EPS of ($0.16) that missed estimates, yet analysts have a consensus "Moderate Buy" with a target of $8.

JPMorgan Chase & Co. lifted its holdings in Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 180.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,135,444 shares of the company's stock after buying an additional 1,375,029 shares during the quarter. JPMorgan Chase & Co. owned 0.80% of Sana Biotechnology worth $7,581,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of SANA. Marex Group plc purchased a new position in Sana Biotechnology in the second quarter worth $10,423,000. Vanguard Group Inc. boosted its position in shares of Sana Biotechnology by 19.9% during the 3rd quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company's stock worth $32,408,000 after purchasing an additional 1,517,474 shares in the last quarter. Baillie Gifford & Co. boosted its position in shares of Sana Biotechnology by 13.6% during the 3rd quarter. Baillie Gifford & Co. now owns 11,436,503 shares of the company's stock worth $40,600,000 after purchasing an additional 1,371,775 shares in the last quarter. Corient Private Wealth LLC grew its stake in shares of Sana Biotechnology by 264.7% during the 2nd quarter. Corient Private Wealth LLC now owns 1,136,000 shares of the company's stock worth $3,101,000 after purchasing an additional 824,505 shares during the period. Finally, Millennium Management LLC grew its stake in shares of Sana Biotechnology by 103.1% during the 3rd quarter. Millennium Management LLC now owns 1,620,000 shares of the company's stock worth $5,751,000 after purchasing an additional 822,423 shares during the period. Institutional investors and hedge funds own 88.23% of the company's stock.

Sana Biotechnology Trading Down 3.2%

Shares of NASDAQ SANA opened at $2.68 on Tuesday. The company's 50-day moving average price is $3.83 and its 200 day moving average price is $4.14. Sana Biotechnology, Inc. has a 52 week low of $1.26 and a 52 week high of $6.55. The stock has a market cap of $715.21 million, a price-to-earnings ratio of -2.76 and a beta of 1.96.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.03). As a group, research analysts expect that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently commented on SANA shares. Weiss Ratings reiterated a "sell (e+)" rating on shares of Sana Biotechnology in a research note on Monday, December 29th. HC Wainwright lowered their target price on shares of Sana Biotechnology from $9.00 to $7.00 and set a "buy" rating on the stock in a research report on Wednesday, March 4th. Wall Street Zen cut shares of Sana Biotechnology from a "hold" rating to a "sell" rating in a report on Saturday, February 7th. Morgan Stanley reiterated an "overweight" rating and set a $12.00 price target on shares of Sana Biotechnology in a research report on Friday, March 13th. Finally, Bank of America boosted their price target on Sana Biotechnology from $6.00 to $7.00 and gave the stock a "buy" rating in a research note on Tuesday, January 6th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $8.00.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company's core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.